PFE Pfizer Inc

$22.98

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

About Pfizer Inc

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Website: https://www.pfizer.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
78003
Address
235 E 42ND ST, NEW YORK, NY, US
Valuation
Market Cap
$125.57B
P/E Ratio
15.70
PEG Ratio
0.53
Price to Book
1.42
Performance
EPS
$1.41
Dividend Yield
7.77%
Profit Margin
12.60%
ROE
9.06%
Technicals
50D MA
$25.11
200D MA
$27.20
52W High
$30.55
52W Low
$20.91
Fundamentals
Shares Outstanding
6B
Target Price
$30.16
Beta
0.60

PFE EPS Estimates vs Actual

Estimated
Actual

PFE News & Sentiment

May 09, 2025 • Benzinga SOMEWHAT-BULLISH
New FDA Leadership Could Raise The Bar For Drug Approvals
New FDA Leadership Team: The FDA's top leadership has shifted under Commissioner Dr. Marty Makary, with Dr. Vinayak "Vinay" Prasad now heading the Center for Biologics Evaluation and Research ( CBER ) and Dr. Sanjula Jain-Nagpal serving as Associate Director of Policy & Research Strategy in the ...
May 09, 2025 • Benzinga NEUTRAL
Generic Drugs Market size is projected to reach USD 594.99 billion by 2031, With growing at a CAGR of 5.0% | The Insight Partners
US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global Generic Drugs Market is growing owing to patent expiry and loss of market exclusivity, along with increasing government initiatives to promote the use of generic drugs.
May 09, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Pfizer ( PFE ) Just Overtook the 20-Day Moving Average
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
May 09, 2025 • Zacks Commentary SOMEWHAT-BULLISH
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
May 08, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, May 08, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, ...
May 08, 2025 • Benzinga NEUTRAL
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks 3 Pharma ETFs To Watch As Trump Turns Up The Heat On Drugmakers - AstraZeneca ( NASDAQ:AZN ) , iShares U.S. Pharmaceutical ETF ( ARCA:IHE )
Trump's push to tie Medicaid drug prices to lower international benchmarks could erase $1 trillion in revenues over 10 years. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.
Sentiment Snapshot

Average Sentiment Score:

0.145
50 articles with scored sentiment

Overall Sentiment:

Neutral

PFE Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.25 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.67
  • Whisper:
  • Surprise %: 36.5%
Feb 04, 2025
Dec 31, 2024 (Pre market)
0.16 Surprise
  • Reported EPS: $0.63
  • Estimate: $0.47
  • Whisper:
  • Surprise %: 34.0%
Oct 29, 2024
Sep 30, 2024 (Pre market)
0.44 Surprise
  • Reported EPS: $1.06
  • Estimate: $0.62
  • Whisper:
  • Surprise %: 71.0%
Jul 30, 2024
Jun 30, 2024 (Pre market)
0.14 Surprise
  • Reported EPS: $0.60
  • Estimate: $0.46
  • Whisper:
  • Surprise %: 30.4%
May 01, 2024
Mar 31, 2024 (Pre market)
0.3 Surprise
  • Reported EPS: $0.82
  • Estimate: $0.52
  • Whisper:
  • Surprise %: 57.7%
Jan 30, 2024
Dec 31, 2023 (Pre market)
0.32 Surprise
  • Reported EPS: $0.10
  • Estimate: $-0.22
  • Whisper:
  • Surprise %: 145.4%
Oct 31, 2023
Sep 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.17
  • Estimate: $-0.34
  • Whisper:
  • Surprise %: 50.0%
Aug 01, 2023
Jun 30, 2023 (Pre market)
0.1 Surprise
  • Reported EPS: $0.67
  • Estimate: $0.57
  • Whisper:
  • Surprise %: 17.5%
May 02, 2023
Mar 31, 2023 (Pre market)
0.25 Surprise
  • Reported EPS: $1.23
  • Estimate: $0.98
  • Whisper:
  • Surprise %: 25.5%

Financials